BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 23326129)

  • 1. Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma.
    Xu XS; Qu K; Liu C; Zhang YL; Liu J; Song YZ; Zhang P; Liu SN; Chang HL
    World J Gastroenterol; 2012 Dec; 18(48):7242-50. PubMed ID: 23326129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Lee JS; Chon YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kang W; Choi MS; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Kim HY; Kim TH; Yoo K; Ha Y; Kim MN; Lee JH; Hwang SG; Kim SS; Cho HJ; Cheong JY; Cho SW; Park SH; Heo NY; Hong YM; Yoon KT; Cho M; Park JG; Kang MK; Park SY; Kweon YO; Tak WY; Jang SY; Sinn DH; Kim SU;
    Yonsei Med J; 2021 Jan; 62(1):12-20. PubMed ID: 33381930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis.
    Cheng J; Wang W; Zhang Y; Liu X; Li M; Wu Z; Liu Z; Lv Y; Wang B
    PLoS One; 2014; 9(1):e87011. PubMed ID: 24498011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy.
    Paul SB; Sahu P; Sreenivas V; Nadda N; Gamanagatti SR; Nayak B; Shalimar S; Acharya SK
    Scand J Gastroenterol; 2019 Sep; 54(9):1132-1137. PubMed ID: 31483691
    [No Abstract]   [Full Text] [Related]  

  • 5. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis.
    Zhang J; Chen G; Zhang P; Zhang J; Li X; Gan D; Cao X; Han M; Du H; Ye Y
    PLoS One; 2020; 15(2):e0228857. PubMed ID: 32053643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis.
    Wong LL; Naugler WE; Schwartz J; Scott DL; Bhattacharya R; Reyes J; Orloff SL
    Clin Transplant; 2013; 27(1):E72-9. PubMed ID: 23278701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival.
    Riaz A; Ryu RK; Kulik LM; Mulcahy MF; Lewandowski RJ; Minocha J; Ibrahim SM; Sato KT; Baker T; Miller FH; Newman S; Omary R; Abecassis M; Benson AB; Salem R
    J Clin Oncol; 2009 Dec; 27(34):5734-42. PubMed ID: 19805671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.
    Tian BW; Yan LJ; Ding ZN; Liu H; Meng GX; Xue JS; Han CL; Dong ZR; Hong JG; Chen ZQ; Wang DX; Li T
    Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):73-83. PubMed ID: 36476076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma.
    Takada H; Tsuchiya K; Yasui Y; Nakakuki N; Tamaki N; Suzuki S; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Asahina Y; Enomoto N; Izumi N
    Cancer Med; 2016 Nov; 5(11):3111-3120. PubMed ID: 27748052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial disparities in alpha-fetoprotein testing and alpha-fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients.
    Wu G; Wu J; Pan X; Liu B; Yao Z; Guo Y; Shi X; Ding Y
    Cancer Med; 2019 Nov; 8(15):6614-6623. PubMed ID: 31517445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: A meta-analysis.
    He C; Peng W; Liu X; Li C; Li X; Wen TF
    Medicine (Baltimore); 2019 Aug; 98(31):e16557. PubMed ID: 31374020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein.
    Nouso K; Kobayashi Y; Nakamura S; Kobayashi S; Takayama H; Toshimori J; Kuwaki K; Hagihara H; Onishi H; Miyake Y; Ikeda F; Shiraha H; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K
    J Gastroenterol Hepatol; 2011 Jul; 26(7):1195-200. PubMed ID: 21410750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Jeong Y; Yoon SM; Han S; Shim JH; Kim KM; Lim YS; Lee HC; Kim SY; Park JH; Lee SW; Ahn SD; Choi EK; Kim JH
    PLoS One; 2015; 10(8):e0135298. PubMed ID: 26252472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis.
    Xing H; Zheng YJ; Han J; Zhang H; Li ZL; Lau WY; Shen F; Yang T
    Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):487-495. PubMed ID: 30257796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
    Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
    BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma.
    Wu MT; He SY; Chen SL; Li LF; He ZQ; Zhu YY; He X; Chen H
    BMC Cancer; 2019 Jun; 19(1):538. PubMed ID: 31164099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Role of Basal Serum Alpha-Fetoprotein in Patients with Hepatocellular Carcinoma Suitable for Curative Treatment.
    Mazza S; Frigerio C; Alfieri D; Mauro A; Torello Viera F; Scalvini D; Barteselli C; Sgarlata C; Veronese L; Bardone M; Rovedatti L; Agazzi S; Strada E; Pozzi L; Maestri M; Ravetta V; Anderloni A
    Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792876
    [No Abstract]   [Full Text] [Related]  

  • 19. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
    Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
    Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy.
    Zhou D; Liu X; Wang X; Yan F; Wang P; Yan H; Jiang Y; Yang Z
    BMC Cancer; 2021 Mar; 21(1):246. PubMed ID: 33685417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.